Biotech News

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (ALXO)ALX Oncology2026-06-25 13:46 ESTClinical readout

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens

Open original release

Related news

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

ALXOALX Oncology2026-06-25 13:46 EST

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology Announces Pricing of Underwritten Offering

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-25 13:46 EST

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

View all latest news

ALX Oncology

ALX Oncology is an oncology-focused biopharmaceutical company centered on cancer programs, with investors watching clinical data, regulatory milestones, and the commercial path for its lead assets.

Recent company news

ALXOALX Oncology2026-06-26 06:10 EST

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALXOALX Oncology2026-06-26 06:10 EST

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-26 06:10 EST

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

ALXOALX Oncology2026-06-26 06:10 EST

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

ALXOALX Oncology2026-06-26 06:10 EST

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States